Overview

Sargramostim (GM-CSF) + PD-1

Status:
Recruiting
Trial end date:
2023-06-09
Target enrollment:
Participant gender:
Summary
This research study is testing the combination of two drugs, sargramostim and pembrolizumab. The study is designed to see if the combination of these study drugs would improve the control of unresectable or metastatic melanoma cancer when compared to use of these drugs alone. The names of the study drugs involved in this study are: - Pembrolizumab - Sargramostim (GM-CSF)
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Partner Therapeutics (PTx)
Treatments:
Pembrolizumab
Sargramostim